"China delivered significant revenue growth at 30% year-over-year, driven by strong customer demand in both Type A and B markets... the Tomo C system expands our product portfolio in China and allows us to compete in the largest and fastest-growing segment of the China radiotherapy market, the Type B segment."
— Suzanne Winter
03Detailed Report
ARAY
Accuray Incorporated
Period
Q1 2025
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 24, 2026
Swipe to view all report sections
Executive Summary
Accuray reported a modestly softer quarter on a revenue basis but delivered meaningful growth in recurring service revenues and a robust backlog that underscores visibility into the company’s long-term growth trajectory. Total net revenue of $102.0 million declined 2% year over year (YoY) and was flat on a constant-currency basis, driven by a 9% drop in product revenue to $48.0 million and a 5% rise in service revenue to $53.0 million. The quarter highlighted regionally diverse dynamics: China grew revenue by 30% YoY as Tomo C shipments begin to contribute and as the company ramps production for the China JV, while APAC saw multiple first-in-country shipments and Europe/Japan experienced softer year-over-year comparisons after record shipments in the prior year. Backlog remained strong at about $469 million, with a book-to-bill ratio of 1.1, supporting revenue visibility over the next several quarters. However, gross margins contracted to 33.9% from 38.0% a year ago, and the company reported a GAAP operating loss of $2.1 million (operating margin of –2.12%), with adjusted EBITDA of $3.1 million (versus $6.5 million a year ago). The company attributes near-term margin volatility to JV margin deferrals in China, which management expects to unwind meaningfully in FY2025, contributing approximately $3–$4 million of incremental EBITDA as the deferral reverses, then normalizing thereafter. Management concluded the quarter with a modest upgrade to full-year guidance, reflecting improving demand in high-growth markets and continued progress on margin expansion initiatives. Looking ahead, Accuray raised its FY2025 revenue guidance to $462–$472 million and adjusted EBITDA guidance to $28–$30 million, contingent on a second-half recovery in the U.S. market and continued strength in emerging markets like China and APAC. The company also highlighted strategic product initiatives (Tomo C in China, Helix for emerging markets), the Adaptive Radixact ecosystem (Cenos, ClearRT, VitalHold), and ongoing ERP-driven productivity gains as catalysts for sustained margin expansion.
Key Performance Indicators
Revenue
Decreasing
101.55M
QoQ: -24.38% | YoY: -2.26%
Gross Profit
Decreasing
34.47M
33.94% margin
QoQ: -10.36% | YoY: -12.72%
Operating Income
Decreasing
-2.15M
QoQ: -131.52% | YoY: -197.11%
Net Income
Decreasing
-3.95M
QoQ: -216.74% | YoY: -33.18%
EPS
Decreasing
-0.04
QoQ: -216.18% | YoY: -28.66%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue and mix: Q1 revenue of $102.0m, down 2% YoY and down 2% CC; product revenue $48.0m (-9% YoY, -9% CC); service revenue $53.0m (+5% YoY, +6% CC). Gross margin: 33.9% (vs 38.0% YoY). Operating income: –$2.1m (operating margin –2.12%); Adjusted EBITDA: $3.1m (vs $6.5m prior year). Net income: –$3.95m (EPS –$0.0395). Cash flow: operating cash flow –$7.29m; free cash flow –$8.41m. Backlog and orders: product gross orders ~$55m; book-to-bill 1.1; backlog ~ $469m (youngest 30 months). Balance sheet: cash and equivalents $60m; total debt $208.8m; net debt $149.6m; inventory up to $155m; accounts receivable ~$92m. Backdrop: management cites longer sales cycles for capital equipment, plus JV margin deferral in China as a near-term earnings headwind; expectation of consistent improvement in H2 FY2025 as Tomo C shipments yield deferred margin release and as China volumes normalize. Guidance: modest raise for FY2025 amid expectations of U.S. recovery in H2 and ongoing demand in emerging markets, with margin expansion and cost efficiencies from ERP integration and productivity programs as accelerants to profitability.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
101.55M
-2.26%
-24.38%
Gross Profit
34.47M
-12.72%
-10.36%
Operating Income
-2.15M
-197.11%
-131.52%
Net Income
-3.95M
-33.18%
-216.74%
EPS
-0.04
-28.66%
-216.18%
Key Financial Ratios
Gross Profit Margin
Fair
33.90%
Gross profit margin is moderate, room for improvement in cost management
Operating Profit Margin
Weak
-0.02%
Operating margin is below industry norms, profitability concerns
Net Profit Margin
Weak
-0.04%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
-0.01%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.09%
Return on equity suggests inefficient capital allocation
Current Ratio
Healthy
1.63
Current ratio shows adequate liquidity to meet short-term obligations
Debt to Equity
High Risk
4.62
Debt-to-equity indicates high leverage and elevated financial risk
P/E Ratio
Negative
-11.41x
Negative earnings make P/E ratio not meaningful
Price to Book
Premium
3.99x
Trading at premium to book value, reflects strong intangibles or growth
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.